Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

Legend Biotech announced its Q2 earnings, reporting $439m of revenues for its only commercial product, the cell therapy ...

Key Points Collaboration and license revenue (GAAP) for Q2 2025 was $8.1 million but missed Q2 2025 GAAP revenue estimates by $0.11 million. Net loss (GAAP) widened to $15.8 million, with increased ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

The Ulcerative Colitis treatment paradigm is undergoing a dynamic evolution, marked by increasing therapeutic interventions ...

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

Kymera Therapeutics' Q2 2025 earnings call highlights clinical progress, Gilead and Sanofi partnerships, and financial strength, setting a strong stage ...